Oncology
KRAS Mutation: Powerful Molecular Predictor of Cetuximab Response in Patients With Metastatic Colorectal Cancer

Pierre Laurent-Puig

Bill Hait
REFERENCE: ABSTRACT: 5671, American Association for Cancer Research, April 14-18, 2007, Los Angeles
PIERRE LAURENT-PUIG, Hôpital Européen Georges Pompidou, Paris
COMMENT: BILL HAIT, Johnson & Johnson, Raritan, NJ
The presence of the KRAS mutation in tumor samples from patients with colorectal cancer gives clear prognostic information about the effectiveness of therapy with the epidermal growth factor receptor inhibitor cetuximab. This is the finding of a group from Paris reported at the American Association for Cancer Research 2007 Annual Meeting held in Los Angeles. Peter Goodwin discussed research findings with Pierre Laurent-Puig.
Bill Hait, President of the American Association for Cancer Research, commented on the findings from Paris discussed by Pierre Laurent-Puig about the value of the KRAS mutation in predicting the response of patients with metastatic colorectal cancer to therapy with cetuximab.
Similar Interviews
When Good Cells Go Bad: The Stem Cell Origin of Cancers
DAVID JABLONS, University of California, San Francisco
REFERENCE: Keynote Lecture, Perspectives in Lung Cancer Conference, 2-3 March 2007, Seville, Spain
Cell signalling
Audio Journal of Oncology in Advance - April 15th, 2007 - Bisphosphonates Recommended for Lung Cancer Bone Metastases
PETER HARPER, Guy’s Hospital, London
REFERENCE: “Management of Tumour and Treatment Related Symptoms” section, Perspectives in Lung Cancer, Seville
Bisphosphonates may be
Two New Second-Line Options For Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Jean-Yves Douillard
Gordon McVie
REFERENCE: Abstracts: 6507 & 2LB, ECCO 14, The European Cancer
[...] post by admin delivered by Medtrials and [...]